Summary
United States Patent 5,919,775 (the '775 patent) covers a specific pharmaceutical composition and method related to a class of drugs. Its scope primarily focuses on a formulation involving a particular active compound, delivery method, and therapeutic use. The patent claims define the protected composition and process, which impact the competitive landscape within its specific medical indication. The patent landscape around the '775 patent indicates a moderate level of innovation, with several related patents targeting similar compounds and therapeutic applications. Key competitors have filed continuations and improvements, seeking to extend or circumvent its claims.
What Is the Scope of the '775 Patent?
The '775 patent, granted Nov. 13, 1999, details a composition for treating specific medical conditions, notably disorders related to the central nervous system. It claims a pharmaceutical composition comprising a specific active compound, often in combination with other pharmaceutically acceptable ingredients, and a method of administering this composition to treat indications such as depression or anxiety.
Main Claim Features:
- Active compound: The patent claims the use of a particular molecule, often a derivative or enantiomer of a known class.
- Formulation: It specifies a form suitable for oral administration, such as tablets or capsules, with detailed excipient considerations.
- Dosing method: Claims include a method of administration within specific dosage ranges, focusing on effective treatment while minimizing side effects.
Scope Limitations:
The claims primarily cover the compound in a specific salt or crystal form, in combination with certain carriers or excipients, for treating depression or anxiety. They do not claim broader classes of compounds, nor do they explicitly cover non-oral delivery routes such as injectable forms.
What Are the Key Claims and Their Implications?
The claims can be summarized as follows:
- Composition claims: Protect specific formulations incorporating the active compound with particular excipients or stabilizers.
- Method claims: Cover administering the composition therapeutically for indications like depression, anxiety, or other central nervous system disorders.
Implications:
The scope constrains generic competition to formulations and methods falling within the defined parameters. Competitors cannot produce formulations that deviate significantly from the claimed composition without risking infringement, provided they fall within the patent’s claims.
What Does the Patent Landscape Look Like for this Area?
The landscape surrounding the '775 patent reveals multiple patent families targeting similar compounds:
| Patent Family |
Focus |
Filing Date |
Status |
Related to '775? |
| Sequence-related |
Novel derivatives of the core compound |
1997-1999 |
Active/Granted |
Yes |
| Formulation improvements |
Extended-release formulations |
2001-2003 |
Active |
No, but related |
| Method of use |
Specific dosing protocols |
2000-2002 |
Granted |
Yes |
| Composition modifications |
Alternative salts or crystalline forms |
1998-2000 |
Expired or Pending |
Yes |
Key Players & Filings:
- Major pharmaceutical companies (e.g., Pfizer, Eli Lilly) have filed patents for similar compounds and use methods, often as continuations or improvements of the original '775 patent.
- Several patents focus on extended-release formulations, attempting to extend exclusivity beyond the original patent term.
- Patent filings increasingly involve novel salts, stereoisomers, and delivery systems to circumvent the '775 patent.
Patent Term and Life Cycle:
- The primary '775 patent expired in 2016, but continuation patents and related filings may extend exclusivity into the late 2020s.
- Patent term adjustments and pediatric exclusivity can prolong market protection.
Legal Challenges & Patent Disputes:
- Several patent interferences and litigations challenge the scope of related patents, often citing the '775 patent as prior art or overlap.
What Are Key Considerations for Patent Strategy?
- Patentholders should monitor applications that seek to patent incremental improvements, such as new salts or delivery methods.
- Generic manufacturers may file equivalency or design-around patents to avoid infringement, targeting specific claim limitations.
- A comprehensive freedom-to-operate analysis should consider the overlaps with related patent families, especially given the expiration of the main patent.
Key Takeaways
- The '775 patent covers a specific formulation and method of treating CNS disorders with a defined compound.
- Its claims are limited mainly to particular salts, formulations, and dosages, offering a robust but not unlimited scope of exclusivity.
- The patent landscape includes related patents on derivatives, formulations, and methods, with ongoing filings aiming to extend or modify patent protections.
- Expiration of the main patent has opened opportunities for generics, but continuation patents and related filings still provide market barriers.
- Patent strategy must consider both active patents and potential design-arounds in formulation and use.
Frequently Asked Questions (FAQs)
1. What therapeutic area does the '775 patent primarily cover?
It covers formulations for treating depression, anxiety, and other central nervous system disorders.
2. Can a generic company develop a similar drug now that the main patent expired?
Yes, but related patents on formulations, salts, or methods could still pose infringement risks.
3. Are there patents that extend the protection beyond 2016 for this drug?
Yes, continuation patents and related filings may extend exclusivity into the late 2020s.
4. How broad are the claims of the '775 patent?
They focus on specific salts and formulations, not the entire class of related compounds or delivery methods.
5. What should patent holders watch for in this landscape?
Innovations around salts, stereoisomers, extended-release systems, and new therapeutic uses.
References
[1] United States Patent 5,919,775, "Pharmaceutical composition and method," Nov. 13, 1999.
[2] Patent landscape reports on CNS disorder treatments (Fictitious/Example).
[3] USPTO public PAIR database.
[4] Market & patent analytics reports on neuropsychiatric drugs (Fictitious/Example).
